Notice: This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends SBOT vs. DMAC, ACTU, VSTM, SCPH, INZY, NKTX, GALT, GLSI, CKPT, and LFVNShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include DiaMedica Therapeutics (DMAC), Actuate Therapeutics (ACTU), Verastem (VSTM), scPharmaceuticals (SCPH), Inozyme Pharma (INZY), Nkarta (NKTX), Galectin Therapeutics (GALT), Greenwich LifeSciences (GLSI), Checkpoint Therapeutics (CKPT), and LifeVantage (LFVN). These companies are all part of the "medical" sector. Stellar Biotechnologies vs. DiaMedica Therapeutics Actuate Therapeutics Verastem scPharmaceuticals Inozyme Pharma Nkarta Galectin Therapeutics Greenwich LifeSciences Checkpoint Therapeutics LifeVantage Stellar Biotechnologies (NASDAQ:SBOT) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk. Do institutionals and insiders hold more shares of SBOT or DMAC? 1.7% of Stellar Biotechnologies shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 7.8% of Stellar Biotechnologies shares are owned by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to SBOT or DMAC? In the previous week, DiaMedica Therapeutics had 2 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 2 mentions for DiaMedica Therapeutics and 0 mentions for Stellar Biotechnologies. Stellar Biotechnologies' average media sentiment score of 0.00 beat DiaMedica Therapeutics' score of -0.45 indicating that Stellar Biotechnologies is being referred to more favorably in the media. Company Overall Sentiment Stellar Biotechnologies Neutral DiaMedica Therapeutics Neutral Is SBOT or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. DiaMedica Therapeutics' return on equity of -43.67% beat Stellar Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Stellar Biotechnologies-1,782.64% -51.12% -48.37% DiaMedica Therapeutics N/A -43.67%-40.81% Which has preferable earnings and valuation, SBOT or DMAC? Stellar Biotechnologies has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Stellar Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStellar Biotechnologies$210K214.72-$5.03M-$1.76-4.81DiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-8.39 Does the MarketBeat Community prefer SBOT or DMAC? Stellar Biotechnologies received 141 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. Likewise, 66.48% of users gave Stellar Biotechnologies an outperform vote while only 62.84% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformStellar BiotechnologiesOutperform Votes23466.48% Underperform Votes11833.52% DiaMedica TherapeuticsOutperform Votes9362.84% Underperform Votes5537.16% Do analysts prefer SBOT or DMAC? DiaMedica Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 48.94%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Stellar Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stellar Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDiaMedica Therapeutics beats Stellar Biotechnologies on 9 of the 16 factors compared between the two stocks. Ad Chaikin Analytics50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.09M$6.59B$5.21B$8.86BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-4.814.3563.3213.02Price / Sales214.72357.031,250.4787.30Price / CashN/A53.8240.8736.91Price / Book3.9910.617.196.54Net Income-$5.03M$153.27M$119.54M$226.22M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$8.46-3.2%N/A+202.1%$45.09M$210,000.00-4.8125DMACDiaMedica Therapeutics1.8275 of 5 stars$4.70+12.4%$7.00+48.9%+84.3%$178.74MN/A0.0020ACTUActuate TherapeuticsN/A$8.94-0.7%N/AN/A$175.79MN/A0.0010VSTMVerastem2.7499 of 5 stars$4.00+1.8%$12.50+212.5%-37.8%$174.91M$2.60M0.0050Analyst DowngradeAnalyst RevisionNews CoverageSCPHscPharmaceuticals3.8265 of 5 stars$3.35-3.2%$15.00+347.8%-39.0%$173.14M$13.59M0.0030INZYInozyme Pharma1.7373 of 5 stars$2.81+4.5%$15.71+459.2%-24.1%$172.81MN/A0.0050NKTXNkarta3.3123 of 5 stars$2.45+0.4%$15.00+512.2%-5.4%$172.19MN/A0.00140Analyst ForecastNews CoverageGALTGalectin Therapeutics1.7186 of 5 stars$2.78+2.2%$11.00+295.7%+36.9%$170.71MN/A0.009Analyst UpgradeGLSIGreenwich LifeSciences1.6972 of 5 stars$13.55+4.5%$38.00+180.4%+19.4%$170.49MN/A0.003CKPTCheckpoint Therapeutics3.3387 of 5 stars$3.75+8.1%$12.00+220.0%+79.4%$169.45M$100,000.000.0010LFVNLifeVantage2.8397 of 5 stars$14.20+7.9%N/A+157.7%$164.83M$200.16M44.38260 Related Companies and Tools Related Companies DMAC Competitors ACTU Competitors VSTM Competitors SCPH Competitors INZY Competitors NKTX Competitors GALT Competitors GLSI Competitors CKPT Competitors LFVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SBOT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
